Rating disease progression of Friedreich's ataxia by the International Cooperative Ataxia Rating Scale: analysis of a 603-patient database
- PMID: 23365101
- PMCID: PMC3624678
- DOI: 10.1093/brain/aws309
Rating disease progression of Friedreich's ataxia by the International Cooperative Ataxia Rating Scale: analysis of a 603-patient database
Abstract
The aim of this cross-sectional study was to analyse disease progression in Friedreich's ataxia as measured by the International Cooperative Ataxia Rating Scale. Single ratings from 603 patients with Friedreich's ataxia were analysed as a function of disease duration, age of onset and GAA repeat lengths. The relative contribution of items and subscales to the total score was studied as a function of disease progression. In addition, the scaling properties were assessed using standard statistical measures. Average total scale progression per year depends on the age of disease onset, the time since diagnosis and the GAA repeat length. The age of onset inversely correlates with increased GAA repeat length. For patients with an age of onset ≤14 years associated with a longer repeat length, the average yearly rate of decline was 2.5 ± 0.18 points in the total International Cooperative Ataxia Rating Scale for the first 20 years of disease duration, whereas patients with a later onset progress more slowly (1.8 ± 0.27 points/year). Ceiling effects in posture, gait and lower limb scale items lead to a reduced sensitivity of the scale in the severely affected population with a total score of >60 points. Psychometric scaling analysis shows generally favourable properties for the total scale, but the subscale grouping could be improved. This cross-sectional study provides a detailed characterization of the International Cooperative Ataxia Rating Scale. The analysis further provides rates of change separated for patients with early and late disease onset, which is driven by the GAA repeat length. Differences in the subscale dynamics merit consideration in the design of future clinical trials applying this scale as a neurological assessment instrument in Friedreich's ataxia.
Figures
Similar articles
-
Biological and clinical characteristics of the European Friedreich's Ataxia Consortium for Translational Studies (EFACTS) cohort: a cross-sectional analysis of baseline data.Lancet Neurol. 2015 Feb;14(2):174-82. doi: 10.1016/S1474-4422(14)70321-7. Epub 2015 Jan 5. Lancet Neurol. 2015. PMID: 25566998 Clinical Trial.
-
Progression characteristics of the European Friedreich's Ataxia Consortium for Translational Studies (EFACTS): a 2 year cohort study.Lancet Neurol. 2016 Dec;15(13):1346-1354. doi: 10.1016/S1474-4422(16)30287-3. Lancet Neurol. 2016. PMID: 27839651 Clinical Trial.
-
Delayed-onset Friedreich's ataxia revisited.Mov Disord. 2016 Jan;31(1):62-9. doi: 10.1002/mds.26382. Epub 2015 Sep 21. Mov Disord. 2016. PMID: 26388117
-
Friedreich's ataxia: clinical aspects and pathogenesis.Semin Neurol. 1999;19(3):311-21. doi: 10.1055/s-2008-1040847. Semin Neurol. 1999. PMID: 12194387 Review.
-
Clinical features of Friedreich's ataxia: classical and atypical phenotypes.J Neurochem. 2013 Aug;126 Suppl 1:103-17. doi: 10.1111/jnc.12317. J Neurochem. 2013. PMID: 23859346 Review.
Cited by
-
Neurodegenerative Diseases: New Hopes and Perspectives.Curr Mol Med. 2024;24(8):1004-1032. doi: 10.2174/1566524023666230907093451. Curr Mol Med. 2024. PMID: 37691199 Review.
-
Nicotinamide Riboside Improves Ataxia Scores and Immunoglobulin Levels in Ataxia Telangiectasia.Mov Disord. 2021 Dec;36(12):2951-2957. doi: 10.1002/mds.28788. Epub 2021 Sep 13. Mov Disord. 2021. PMID: 34515380 Free PMC article.
-
Epigenetic promoter silencing in Friedreich ataxia is dependent on repeat length.Ann Neurol. 2014 Oct;76(4):522-8. doi: 10.1002/ana.24249. Epub 2014 Aug 30. Ann Neurol. 2014. PMID: 25112975 Free PMC article.
-
Translating HDAC inhibitors in Friedreich's ataxia.Expert Opin Orphan Drugs. 2016;4(9):961-970. doi: 10.1080/21678707.2016.1215910. Epub 2016 Jul 31. Expert Opin Orphan Drugs. 2016. PMID: 28392990 Free PMC article.
-
Increased brain tissue sodium concentration in Friedreich ataxia: A multimodal MR imaging study.Neuroimage Clin. 2022;34:103025. doi: 10.1016/j.nicl.2022.103025. Epub 2022 Apr 26. Neuroimage Clin. 2022. PMID: 35500368 Free PMC article.
References
-
- Arnold P, Boulat O, Maire R, Kuntzer T. Expanding view of phenotype and oxidative stress in Friedreich's ataxia patients with and without idebenone. Schweiz Arch Neurol Psychiatr. 2006;157:169–76.
-
- Burk K, Malzig U, Wolf S, Heck S, Dimitriadis K, Schmitz-Hubsch T, et al. Comparison of three clinical rating scales in Friedreich ataxia (FRDA) Mov Disord. 2009;24:1779–84. - PubMed
-
- Cano SJ, Hobart JC, Hart PE, Korlipara LV, Schapira AH, Cooper JM. International Cooperative Ataxia Rating Scale (ICARS): appropriate for studies of Friedreich's ataxia? Mov Disord. 2005;20:1585–91. - PubMed
-
- Delatycki MB. Evaluating the progression of Friedreich ataxia and its treatment. J Neurol. 2009;256(Suppl 1):36–41. - PubMed
-
- Di Prospero NA, Baker A, Jeffries N, Fischbeck KH. Neurological effects of high-dose idebenone in patients with Friedreich's ataxia: a randomised, placebo-controlled trial. Lancet Neurol. 2007;6:878–86. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
